U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07104266) titled 'Triple Negative Breast Cancer and Celecoxib. Pilot Study' on July 17.
Brief Summary: Relapses occur in 20 to 30% of patients with early-stage triple-negative breast cancer (TNBC), which is characterized by the absence of three receptors: the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). Radiotherapy (RT) can increase or decrease, depending on the patient, the level of cytokines that promote metastasis development. To help prevent the development of metastasis, the cyclooxygenase-2 (COX-2) inhibitor celecoxib will be administered during RT. This treatment aims to prevent RT-in...